The bill amends sections 28-405 and 28-416 of the Revised Statutes Cumulative Supplement, 2024, to update the schedules of controlled substances under the Uniform Controlled Substances Act. It introduces numerous new substances to Schedule I, including various fentanyl analogs and synthetic opioids, while repealing the original sections that listed these substances. New entries such as Meta-Fluorofentanyl, Isovalerylfentanyl, and several nitazenes are added, reflecting the ongoing opioid crisis. The bill also clarifies definitions, specifying that psilocybin does not include any FDA-approved pharmaceutical compositions, and modifies the classification of tetrahydrocannabinols to include synthetic equivalents.

Additionally, the bill expands the list of controlled substances by including compounds derived from phenethylamine and tryptamine, as well as synthetic analogs with stimulant or depressant effects. It introduces new substances like Mesocarb and Methiopropamine, while removing outdated references. The bill also updates penalties related to the manufacture, distribution, and possession of controlled substances, particularly for offenses involving minors and specific locations. Stricter penalties for violations involving cocaine, heroin, and methamphetamine are established, alongside a focus on treatment and counseling for drug-related offenses. Overall, the bill aims to enhance regulatory oversight and ensure that the legal framework surrounding controlled substances is comprehensive and up-to-date.

Statutes affected:
Introduced: 28-405, 28-416
Final Reading: 28-405, 28-416
Slip Law: 28-405, 28-416